Comparative Pharmacology
Head-to-head clinical analysis: BRETYLIUM TOSYLATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus IBUTILIDE FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETYLIUM TOSYLATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus IBUTILIDE FUMARATE.
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs IBUTILIDE FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bretylium tosylate inhibits norepinephrine release from adrenergic nerve terminals by blocking neuronal reuptake and causing initial norepinephrine release followed by depletion. It also exhibits class III antiarrhythmic activity by prolonging the action potential duration and refractory period in cardiac Purkinje fibers and ventricular muscle.
Ibutilide fumarate is a Class III antiarrhythmic agent that prolongs the atrial and ventricular refractory period by blocking the rapid component of the delayed rectifier potassium current (IKr) and also enhances the slow inward sodium current (INa), resulting in prolongation of the action potential duration and effective refractory period.
For ventricular tachycardia/fibrillation: 5 mg/kg IV over 8-10 minutes, then 5-10 mg/kg IV q6-8h. For continuous infusion: 1-2 mg/min IV.
1 mg (10 mL of 0.1 mg/mL solution) IV infusion over 10 minutes; if arrhythmia persists after 10 minutes post-infusion, a second 1 mg dose may be administered. For patients weighing <60 kg, use 0.01 mg/kg.
None Documented
None Documented
Terminal half-life: 7-11 hours (normal renal function); prolonged in renal impairment (up to 16-32 hours in anuria)
Terminal elimination half-life is 2–12 hours (mean 6 hours). In atrial fibrillation/flutter, the clinically effective half-life allowing for arrhythmia conversion is approximately 2–4 hours due to rapid redistribution.
Renal: >80% unchanged; biliary/fecal: minimal (<5%)
Primarily hepatic metabolism; less than 10% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20% of total clearance.
Category C
Category A/B
Antiarrhythmic (Class III)
Antiarrhythmic (Class III)